<DOC>
	<DOCNO>NCT01522391</DOCNO>
	<brief_summary>The primary objective study evaluate microbial density eczematous lesion two week twice daily therapy investigational product , DPK-060 1 % ointment , compare placebo patient atopic dermatitis . This randomized , double-blind , placebo-controlled part study precede open-label investigation small group patient ( n=5 ) treat two application DPK-060 1 % ointment per day four day assess safety , local tolerability systemic absorption DPK-060 . The secondary objective evaluate severity eczema pruritus , assess tolerability safety treatment assess degree systemic absorption DPK-060 blood Day 7 Day 21 sub-set 10 patient .</brief_summary>
	<brief_title>A Randomized , Double-blinded Placebo-controlled Study Investigate Antimicrobial Efficacy Safety Following Topical Application DPK-060</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>A clinical diagnosis atopic dermatitis Treatable eczematous lesion total area least 25 cm2 ( 100 cm2 initial five patient ) Female patient childbearing potential use appropriate method contraception . Female patient childbearing potential eligible PK data first 10 patient evaluate Medical Products Agency ( Swedish regulatory agency ) give approval include woman childbearing potential . Significant clinical illness , within two week prior first dose , could affect outcome study Previous local systemic antimicrobial therapy within last four week prior first application investigational product ( DPK060 1 % placebo ointment ) Existence surgical medical condition , judgment investigator , might interfere absorption , distribution , metabolism excretion drug Patients systemic treatment atopic dermatitis topical transdermal treatment ( nicotine , hormone replacement therapy ) site eczema within 14 day prior first application DPK060 1 % placebo ointment and/or topical treatment tar , corticosteroid , topical immunomodulators oral treatment corticosteroid within 14 day prior first application and/or oral antihistamine within 14 day first dose . A need medication period 0 7 day entry study , ( exclude oral contraceptive pill female ) except deem principal investigator / clinical investigator interfere outcome study Diagnosis skin disease , opinion investigator , likely adversely affect outcome study History evidence significant cardiac , renal , hepatic endocrine disease Significant hypersensitivity allergy , judge investigator Immunocompromised patient Lice scabies Tinea corporis Hypersensitivity ingredient vehicle The presence prominent tattoo sit application DPK060 1 % placebo ointment Donation blood , exceed 450 mL , three month prior first dose Participation clinical study 12 week prior first dose Ongoing alcohol drug abuse Positive pregnancy test lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>